Skip to content
Medical Health Aged Care

Dr Fei Sim re-elected as National President

Pharmaceutical Society of Australia (PSA) 2 mins read

The Pharmaceutical Society of Australia (PSA) has re-elected Dr Fei Sim FPS as National President and Chair of the National Board in Canberra today.

The Board also elected Caroline Diamantis MPS and Benjamin Marchant MPS as National Vice-Presidents for the term beginning 1 July 2023. Dr Shane Jackson FPS was also appointed to lead PSA’s approach to the Community Pharmacy Agreement and will remain a part of the Board executive.  

PSA Interim Chief Executive Officer Nick Foster welcomed incoming Board Directors Dr Natalie Soulsby FPS, Amanda Cross MPS and Helen Benson MPS.

“I am excited at to work with a PSA board with such a wealth of experience across all sectors of pharmacy,” Mr Foster said.

“I particularly welcome new Directors Dr Natalie Soulsby, Amanda Cross and Helen Benson, who are all experienced, passionate pharmacists who bring a wealth of experience to our organisation. 

“PSA is proud to welcome a Board that reflects our profession, with more than half of our incoming Board being women.

“I look forward to working closely with the newly appointed Board and our re-elected President to best support Australia’s pharmacists.”

Dr Sim, who was first elected as President in June 2021, said it was an honour to be re‑elected and continue her advocacy for pharmacists during a time of rapid change.

“Despite the challenges that our profession faces, I am confident in the future of our profession,” Dr Sim said.

“With the support of the PSA Board, we continue to work toward a future that recognises the skills and expertise of pharmacists and allows us to practice to our top of scope.

“This is my priority and the priority of our entire team.

“Thank you, PSA members, for your support. I am humbled and proud to be able to continue leading you and our profession.

“I would also like to thank retiring Board members Michelle Lynch FPS, Warwick Plunkett FPS, Andrew Sluggett FPS, and Deanna Mill MPS for their service to our profession,” Dr Sim concluded.

The incoming Board of Directors includes:

  • Dr Fei Sim FPS, National President (Western Australia)
  • Caroline Diamantis MPS, National Vice-President (New South Wales)
  • Benjamin Marchant MPS, National Vice-President (Victoria)
  • Dr Shane Jackson FPS, Board Executive member (Tasmania)
  • Helen Benson MPS, Board Director (New South Wales)
  • Amanda Cross MPS, Board Director (Victoria)
  • Prof. Mark Naunton MPS, Board Director (Australian Capital Territory)
  • Dr Natalie Soulsby FPS, Board Director (South Australia)
  • Bridget Totterman MPS, Board Director (Queensland)

New appointments will commence on 1 July 2023.

 

Media contact:   Georgia Clarke   M: 0480 099 798      E: [email protected]

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s 36,000 pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.

More from this category

  • Medical Health Aged Care
  • 17/12/2025
  • 13:11
GE HealthCare

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases.…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/12/2025
  • 12:03
Jane Morgan Management

LTR Pharma surpasses 1,000 SPONTAN® prescriptions under TGA Special Access Scheme

Highlights More than 1,000 SPONTAN® prescriptions issued under the TGA Special Access Scheme Growing prescriber network with continued uptake in complex ED cases, including post-prostate cancer patients Real-world insights informing US commercial strategy ahead of ROXUS® launch in H1 CY2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that more than 1,000 SPONTAN® prescriptions have now been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category B). SPONTAN is being prescribed for patients with unmet clinical needs, including men who have not achieved adequate benefit from traditional oral PDE5 inhibitor…

  • Contains:
  • Engineering, Medical Health Aged Care
  • 17/12/2025
  • 09:02
UNSW Sydney

UNSW students claim victory in international artificial heart competition

A team of undergraduate engineering students from UNSW Sydney has claimed first place at a prestigious international artificial heart design competition in Vienna. The…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.